Terms of the deal were not disclosed, though it is has been established that, as in the prior recent acquisition, the brand will be extended with a renaming: The company will soon be officially rechristened as Gedeon Richter Mexico S.A.P.I. de C.V.
In an official statement, Gedeon Richter conveyed its intent to buy the outstanding 30% by 2017; the agreement with Next Pharma allowed for the future acquisition of remaining shares in that company.
According to a Reuters report, Richter seeks to register female healthcare therapy products through DNA Pharmaceuticals, “focusing primarily on Esmya, Richter’s drug to treat uterine fibroids, and the establishment of a related sales network.”
Said Richter CEO Erik Bogsch in announcing the deal, “this cooperation with DNA is another strategic move aimed at the diversification of Richter’s geographic presence in Latin America, one of the regions with the fastest-growing pharmaceutical markets worldwide.”
For 2012, Gedeon Richter reported consolidated sales of approximately $1.5 billion and market capitalization of $3.1 billion.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
